Case Report: Durable complete response of advanced-stage hepatocellular carcinoma to DEB−TACE combined with lenvatinib and camrelizumab
BackgroundHepatocellular carcinoma (HCC) with lung metastases is associated with a poor prognosis due to limited effective treatment options. Emerging evidence suggests that combining locoregional therapy, multi-kinase inhibitors (MKIs), and immune checkpoint inhibitors (ICIs) offers promising resul...
Saved in:
| Main Authors: | Baiguo Xu, Yufeng Cui, Ning Wang, Zhongsong Gao, Qing Ye, Huiling Xiang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-06-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1549675/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Transarterial Chemoembolization Plus Camrelizumab and Rivoceranib versus Camrelizumab and Rivoceranib Alone for BCLC Stage C Hepatocellular Carcinoma
by: Zhou WJ, et al.
Published: (2024-12-01) -
Efficacy, safety, and biomarker analysis of TACE combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a real-world study
by: Lingzhan Meng, et al.
Published: (2024-11-01) -
TACE versus TARE for patients with hepatocellular carcinoma: Overall and individual patient level meta analysis
by: Andrew M. Brown, et al.
Published: (2023-02-01) -
Discussion on the duration of response following HBsAg clearance in patients with chronic hepatitis B treated with PegIFNα-2b
by: Tao Wang, et al.
Published: (2025-04-01) -
Current insights and trends in atopic dermatitis and microbiota interactions: a systematic review and bibliometric analysis
by: Zhongsong Zhang, et al.
Published: (2025-06-01)